Tirzepatide vs Retatrutide
A dual GIP and GLP-1 receptor agonist — the first of the co-agonists. An investigational GIP/GLP-1/glucagon triple receptor agonist. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Tirzepatide | Retatrutide | |
|---|---|---|
| Also known as | Mounjaro, Zepbound | — |
| Type | Analog | Analog |
| Evidence | Established | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Dual GIP/GLP-1 receptor agonist (39 aa, acylated) | GIP/GLP-1/glucagon triple agonist (acylated peptide) |
| Receptor | GIP receptor + GLP-1 receptor | GIP + GLP-1 + glucagon receptors |
| Molecular weight | ~4,813.5 Da | ≈4,900 Da |
| Half-life | ||
| Based on | Glucose-dependent insulinotropic polypeptide | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Tirzepatide and Retatrutide?
- Tirzepatide is an engineered analog based on Glucose-dependent insulinotropic polypeptide; Retatrutide is an engineered analog based on Glucagon-like peptide-1. Tirzepatide signals at GIP receptor + GLP-1 receptor; Retatrutide signals at GIP + GLP-1 + glucagon receptors.
- How do the half-lives of Tirzepatide and Retatrutide compare?
- The reported circulating half-life of Tirzepatide is ~5 days (~120 h); Retatrutide is ~6 days. These are reference values for the native or representative form — educational only, not dosing advice.
- Is Tirzepatide the same as Mounjaro?
- Mounjaro, Zepbound are brand names of Tirzepatide. This comparison describes the molecules, not branded products.
Prefer the other order? Retatrutide vs Tirzepatide. Or open the interactive comparison tool to add more molecules.